Instil Bio, Inc.
DALLAS, TX · Founded 2018 · CIK 0001789769 · Biotech · Public
CAR-T cell therapies for hematologic malignancies and solid tumors
instilbio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $371M
- 4 Form D · Feb 2021
- 68 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 33
- 1 granted · 32 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $15,000,000 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $170,199,973 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $515,917 | |
| Private capital raised | Form D · SEC | $185,449,881 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2778 | Genetic Networks, LLC | — | — |
| 2779 | FLUIDFORM INC | — | — |
| 2780 | Tentarix | — | — |
| 2781 | Instil Bio, Inc. | — | $371M |
| 2782 | Legend Biotech Corp | — | $350M |
| 2783 | Sensei Biotherapeutics, Inc. | — | $349M |
| 2784 | X4 Pharmaceuticals | — | $313M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Gwen BinderDirector
- Bronson CrouchDirector · Executive Officer
- Neil GibsonDirector
- Robert HawkinsDirector
- Sandeep LaumasExecutive Officer
- George MatchamDirector
- Kent McGaughyDirector
- Mariam MorrisExecutive Officer
- Jack NielsenDirector
- Margo RobertsDirector
- Nimish ShahDirector
Patents
- Processing Of Tumor Infiltrating Lymphocytesapplication
- Methods Of Isolating Of Tumor Infiltrating Lymphocytes And Use Thereofapplication
- Processing Of Tumor Infiltrating Lymphocytesapplication
- Receptors Providing Targeted Costimulation For Adoptive Cell Therapygranted
- Receptors Providing Targeted Costimulation For Adoptive Cell Therapyapplication
- Receptors Providing Targeted Costimulation For Adoptive Cell Therapyapplication
- Tumor Infiltrating Lymphocytes And ANTI-PD-1 Antibody Combination Therapy For The Treatment Of Cancerapplication
- Tumor-infiltrating Lymphocyte (til) Compositions And Uses Thereofapplication
- Methods For Identifying Tcr Repertoire And Compositions And Uses Thereofapplication
- Receptors Providing Targeted Costimulation For Adoptive Cell Therapyapplication
- Processing Of Tumor Infiltrating Lymphocytesapplication
- Tumor Infiltrating Lymphocytes And ANTI-PD-1 Antibody Combination Therapy For The Treatment Of Cancerapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.